Optic nerve gliomas (ONGs) in children are uniformly low-grade gliomas that frequently cause vision loss. Optic nerve gliomas in adults are reported to be more clinically aggressive with frequent transformation into high-grade gliomas. We report a child with sporadic ONG and an aggressive clinical course. Tumor molecular characterization identified KIAA1549-BRAF fusion but also set domain-containing protein 2 (SETD2; OMIM, 612778) mutation, previously reported only, to our knowledge, in high-grade gliomas and non–central nervous system cancers.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Campbell AA, Gartrell-Corrado RD, Mansukhani M, et al. SETD2 Mutation in an Aggressive Optic Nerve Glioma. JAMA Ophthalmol. Published online November 07, 2019. doi:https://doi.org/10.1001/jamaophthalmol.2019.4511
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: